Table 1.
Baseline characteristics of patients in chronic spontaneous urticaria (CSU) clinical trials—all treatment arms pooled
| Characteristic | ASTERIA I, N = 318 | ASTERIA II, N = 322 | GLACIAL, N = 335 |
|---|---|---|---|
| Age [years; mean (SD)] | 41.2 (14.5) | 42.5 (13.7) | 43.1 (14.1) |
| Sex: male [n (%)] | 87 (27.4) | 78 (24.2) | 94 (28.1) |
| Weight | |||
| Mean [kg (SD)] | 82.2 (21.0) | 82.4 (21.9) | 83.9 (22.5) |
| Median (kg) | 80.0 | 79.0 | 79.6 |
| Range (kg) | 35 to 138 | 43 to 188 | 46 to 172 |
| <80 kg [n (%)] | 158 (49.7) | 166 (51.6) | 168 (50.1) |
| Duration of CSU | |||
| Mean [years (SD)] | 6.9 (9.1) | 6.5 (8.6) | 7.4 (9.5) |
| Range (years) | 0.5 to 50.5 | 0.5 to 66.4 | 0.5 to 54.1 |
| >10 years (%) | 21.7 | 19.1 | 24.0 |
| UAS7 | |||
| Mean (SD) | 31.1 (6.6) | 30.7 (6.8) | 30.9 (6.6) |
| Range | 16.0 to 42.0 | 16.5 to 42.0 | 16.0 to 42.0 |
| Weekly itch severity score | |||
| Mean (SD) | 14.3 (3.5) | 14.0 (3.7) | 14.0 (3.6) |
| Range | 8.0 to 21.0 | 8.0 to 21.0 | 7.5 to 21.0 |
| Score <13 (%) | 34.0 | 43.8 | 39.1 |
| Presence of angioedema (%) | 47.5 | 40.7 | 53.1 |
| Previous medications for CSU: overall [n (%)] | 318 (100.0) | 322 (100.0) | 335 (100.0) |
| Antihistamines | 317 (99.7) | 322 (100.0) | 335 (100.0) |
| Histamine H2 blockers | 93 (29.2) | 113 (35.1) | 297 (88.7) |
| Immunosuppressants | 29 (9.1) | 26 (8.1) | 34 (10.1) |
| Ciclosporin | 26 (8.2) | 24 (7.5) | 23 (6.9) |
| LTRAs | 83 (26.1) | 83 (25.8) | 195 (58.2) |
| Other | 148 (46.5) | 143 (44.4) | 197 (58.8) |
| Dapsone | 5 (1.6) | 8 (2.5) | 11 (3.3) |
| Omalizumab | 4 (1.3) | 2 (0.6) | 2 (0.6) |
| Steroids | 159 (50.0) | 161 (50.0) | 194 (57.9) |
| EQ-5D utility [mean (SD)] | 0.68 (0.27) | 0.71 (0.26) | 0.73 (0.24) |
| Range | −0.08 to 1 | −0.08 to 1 | −0.23 to 1 |
LTRA leukotriene receptor antagonist, SD standard deviation, UAS7 Urticaria Activity Score over 7 days